![](/images/graphics-bg.png)
Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma
Joint Authors
Ron, I. G.
Zwas, S. T.
Lotem, Michal M.
Tamar, Peretz
Galun, E.
Revskaya, E.
Casadevall, A.
Dadachova, Ekaterina
Mizrachi, S.
Jacob, Schachter
Friedmann, N.
de Kater, A. W.
Klutzaritz, V.
Kennedy, J. A.
DeNardo, S. J.
Iosilevsky, G.
Chisin, R.
Banaga, E.
Thornton, G. B.
Liberman, Y.
DeNardo, G. L.
Klein, M.
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-01-10
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
There is a need for effective “broad spectrum” therapies for metastatic melanoma which would be suitable for all patients.
The objectives of Phase Ia/Ib studies were to evaluate the safety, pharmacokinetics, dosimetry, and antitumor activity of 188Re-6D2, a 188-Rhenium-labeled antibody to melanin.
Stage IIIC/IV metastatic melanoma (MM) patients who failed standard therapies were enrolled in both studies.
In Phase Ia, 10 mCi 188Re-6D2 were given while unlabeled antibody preload was escalated.
In Phase Ib, the dose of 188Re-6D2 was escalated to 54 mCi.
SPECT/CT revealed 188Re-6D2 uptake in melanoma metastases.
The mean effective half-life of 188Re-6D2 was 12.4 h.
Transient HAMA was observed in 9 patients.
Six patients met the RECIST criteria for stable disease at 6 weeks.
Two patients had durable disease stabilization for 14 weeks and one for 22 weeks.
Median overall survival was 13 months with no dose-limiting toxicities.
The data demonstrate that 188Re-6D2 was well tolerated, localized in melanoma metastases, and had antitumor activity, thus warranting its further investigation in patients with metastatic melanoma.
American Psychological Association (APA)
Klein, M.& Lotem, Michal M.& Tamar, Peretz& Zwas, S. T.& Mizrachi, S.& Liberman, Y.…[et al.]. 2013. Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma. Journal of Skin Cancer،Vol. 2013, no. 2013, pp.1-8.
https://search.emarefa.net/detail/BIM-501413
Modern Language Association (MLA)
Klein, M.…[et al.]. Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma. Journal of Skin Cancer No. 2013 (2013), pp.1-8.
https://search.emarefa.net/detail/BIM-501413
American Medical Association (AMA)
Klein, M.& Lotem, Michal M.& Tamar, Peretz& Zwas, S. T.& Mizrachi, S.& Liberman, Y.…[et al.]. Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma. Journal of Skin Cancer. 2013. Vol. 2013, no. 2013, pp.1-8.
https://search.emarefa.net/detail/BIM-501413
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-501413